Clinical trials: Gram-negative Bacteremia
Enterobacteriaceae Infections, Bloodstream Infection
Antibiotic Treatment Duration (7 vs 14 Days) Comparison in Blood Stream Infection Causes by Enterobacteriaceae
The antimicrobial crisis is a real problem. Infections produced by multiresistant bacteria are becoming more and more frequent, and available antimicrobial agents are usually scarce.
- Trial name
- SHORTEN (NCT02400268)
- Testing
- 7 days course of antibiotic treatment, 14 days course of antibiotic treatment
- Where
- 4 sites in Spain
- Volunteers
- 238 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Bacterial Infections, Bone Diseases, Infectious
Fosfomycin I.v. for Treatment of Severely Infected Patients
The purpose of this European, multicentric, prospective, non-interventional study is to document and evaluate the efficacy and safety of the treatment of severely infected patients with intravenously administered fosfomycin…
- Conditions
- Bacterial Infections, Bone Diseases, Infectious, Osteomyelitis, Central Nervous System Bacterial Infections
- Trial name
- FORTRESS (NCT02979951)
- Where
- 50 sites in Austria, Germany and 3 more
- Volunteers
- 1,000 people
- Sponsor
- Infectopharm Arzneimittel GmbH
Urinary Tract Infection, Acute Pyelonephritis
Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults
This is an open-label, randomized, multi-center, interventional, active-controlled Phase 4 study to evaluate the efficacy and safety of CAZ-AVI versus BAT in the treatment of infected participants with selected infection types…
- Conditions
- Urinary Tract Infection, Acute Pyelonephritis, Hospital Acquired Pneumonia, Ventilator-associated Pneumonia
- Trial name
- NCT04882085
- Testing
- Zavicefta, Ceftazidime-Avibactam, Best Available Treatment
- Where
- 37 sites in China
- Volunteers
- 60 people
- Sponsor
- Pfizer
Salmonella Typhi Infection
Understanding How Salmonella Typhi Infects Humans (Bottlenecks)
Typhoid fever is an infection caused by the bacteria Salmonella Typhi (S. Typhi). S. Typhi causes disease principally in developing countries where communities do not have access to safe water or adequate sanitation.
- Trial name
- NCT03889067
- Testing
- Salmonella Typhi challenge
- Where
- United Kingdom
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Gram-negative Bacteremia
A Platform Trial for Gram Negative Bloodstream Infections
BALANCE+ is a perpetual multiple domain randomized controlled platform trial to evaluate various treatment strategies for Gram-negative bloodstream infections (GN BSIs).
- Trial name
- BALANCE+ (NCT06537609)
- Testing
- De-escalation VS No De-escalation, Oral beta-lactams VS non beta-lactams, Central vascular catheter retention VS Central vascular catheter replacement
- Where
- 39 sites in Australia, Canada and 3 more
- Volunteers
- 2,500 people
- Sponsor
- Sunnybrook Health Sciences Centre
Gram-negative Bacteremia
Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial
The Gram-negative bloodstream infection Oral Antibiotic Therapy trial (The GOAT Trial) is a multi-center, randomized clinical trial that hypothesizes that early transition to oral antibiotic therapy for the treatment of…
- Trial name
- GOAT (NCT06080698)
- Testing
- Intravenous Antibiotics, Oral Antibiotics
- Where
- 11 sites in United States
- Volunteers
- 1,030 people
- Sponsor
- Johns Hopkins University
Gram Negative Pneumonia, Gram-Negative Bacterial Infections
Clinical Trial to Study the Efficacy and Safety of Fluorothiazinone (N.F. Gamaleya NRCEM) in Prophylaxis of Nosocomial Bacterial Infections With Participation of Patients on MV
This study is designed to evaluate the clinical and antibacterial efficacy, safety and pharmacokinetics of the drug Fluorothiazinone compared to placebo to prevent nosocomial gram-negative bacterial infections with participation…
- Conditions
- Gram Negative Pneumonia, Gram-Negative Bacterial Infections, Bacteremia Caused by Gram-Negative Bacteria
- Trial name
- NCT06135350
- Testing
- Fluorothiazinone, tablets 300 mg at a dose of 2400 mg/day
- Where
- 2 sites in Russia
- Volunteers
- 234 people
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Urinary Tract Infection, Fluoroquinolone
Clinical Impact of Fluoroquinolone Resistance in Bacteremia Caused by Gram-Negative Bacilli of Urinary Tract Origin
The information collected will optimize the management of patients with urinary tract infections with secondary bacteremia, primarily with gram negative bacteria especially Escherichia coli.
- Conditions
- Urinary Tract Infection, Fluoroquinolone, Bacteremia
- Trial name
- NCT00414362
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- University of Pittsburgh
Bacteremia, Pseudomonas Infections
Optimizing Dosing of Colistin for Infections Resistant to All Other Antibiotics, Approved NIH Protocol Dated 12.06.07(DMID Protocol #07-0036)
More than 80 patients at the University of Pittsburgh Medical Center have been infected with Pseudomonas aeruginosa, lacking susceptibility to all commercially available antibiotics except "colistin".
- Trial name
- NCT00235690
- Testing
- Blood draws, Blood draw
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Pittsburgh
Gram-negative Bacteremia, Urinary Tract Infection Bacterial
Shortened Antibiotic Treatment of 5 Days in Gram-negative Bacteremia
GNB5 is an investigator-initiated multicentre non-inferiority randomized controlled trial which aims to assess the efficacy and safety of shortened antibiotic for patients hospitalized with a Gram negative bacteremia with a…
- Trial name
- GNB5 (NCT04291768)
- Testing
- Shortened antibiotic treatment, Standard antibiotic treatment
- Where
- 13 sites in Denmark
- Volunteers
- 380 people
- Sponsor
- Thomas Benfield
Gram-negative Bacteremia, Bacteremia
Clinical Outcomes and Cost of Gram Negative Bacteremia
This study examines the clinical outcomes and healthcare costs associated with gram negative bacteremia at Duke University Medical Center from 2002-2015.
- Trial name
- NCT02599220
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Duke University
Bacteremia, Healthcare-associated Pneumonia
Randomized-controlled Trial (RCT) on Combination Antibiotic for Infections Caused by Gram-negative Bacteria
Background and rationale: Antimicrobial resistance is a global public health threat. An increasing number of Gram-negative bacteria isolates worldwide are resistant to virtually all antibiotics including carbapenems.
- Conditions
- Bacteremia, Healthcare-associated Pneumonia, Ventilator-associated Pneumonia
- Trial name
- XDR-GNB (NCT02134106)
- Testing
- Polymyxin B, Polymyxin B + Doripenem
- Where
- 2 sites in Singapore
- Sponsor
- Tan Tock Seng Hospital
Bacteremia
Detecting Infections Rapidly and Easily for Bacteremia Trial (DIREBT)
To assure the uniform collection, handling, storage and transport of patient whole blood specimens and associated information to support validation of the T2 Bacteremia Assay.
- Trial name
- DIREBT (NCT01919762)
- Where
- United States
- Volunteers
- 156 people
- Sponsor
- T2 Biosystems
Gram-negative Bacteremia, Microbial Colonization
Antimicrobial Resistant Organism Decolonization After Microbiome Perturbation
ARO-DECAMP is a multi-centre, placebo-controlled, pilot and feasibility randomized controlled trial for the microbial consortium Microbial Ecosystem Therapeutic-2.
- Conditions
- Gram-negative Bacteremia, Microbial Colonization, Antibiotic Resistant Infection
- Trial name
- ARO-DECAMP (NCT06214403)
- Testing
- MET-2
- Where
- 4 sites in Canada
- Sponsor
- University Health Network, Toronto
Enterobacteriaceae Infections
Study on Reduced Antibiotic Treatment vs Broad Spectrum Betalactam in Patients With Bacteremia by Enterobacteriaceae
The continuous increase in the bacterial resistance rate and the slow arrival of new therapeutic options have turned into an antibiotic crisis.
- Trial name
- SIMPLIFY (NCT02795949)
- Testing
- Antipseudomonal beta-lactam antibiotic, De-escalation(short-spectrum antibiotic)
- Where
- 21 sites in Spain
- Volunteers
- 344 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Gram-negative Bacteremia
BALANCE+ Vanguard Phase
The goal of the BALANCE+ clinical trial is to transform random care to randomized care for patients with Gram negative bloodstream infections to inform best treatment approaches and optimize outcomes.
- Trial name
- BALANCE+ (NCT05893147)
- Testing
- De-escalation VS No De-escalation, Oral beta-lactams VS non beta-lactams, Central vascular catheter retention VS Central vascular catheter replacement
- Where
- 10 sites in Canada
- Volunteers
- 174 people
- Sponsor
- Sunnybrook Health Sciences Centre
Escherichia Coli Bacteremia, Klebsiella Bacteraemia
Switch to Oral Antibiotics in Gram-negative Bacteremia
Eligible subjects will be those age 18 years or more with mono-microbial blood stream infection caused by E. coli, Klebsiella species, Enterobacter species, Serratia species, Citrobacter species, or Proteus species, who have…
- Conditions
- Escherichia Coli Bacteremia, Klebsiella Bacteraemia, Enterobacter Bacteraemia, Serratia Bacteraemia
- Trial name
- SOAB (NCT04146922)
- Testing
- Step down to oral antimicrobial therapy, IV antimicrobial therapy
- Where
- 7 sites in Bahrain, Kuwait and 2 more
- Volunteers
- 176 people
- Sponsor
- Hamad Medical Corporation
Gram-negative Bacteremia, Intensive Care Patients
Impact of Real-time MIC (Minimum Inhibitory Concentration) Reporting (<6 Hours) on β-lactam Prescription in Cases of Gram-negative Bacilli Bacteremia in ICU Patients in Real-life Settings
Evaluate the impact of rapid, real-time (4 to 6 h) MIC reporting compared with the standard method (=diffusion antibiotic susceptibility testing) (18 to 24 h) on β-lactam prescribing in terms of the choice of molecule by the…
- Trial name
- CMIBActRéa (NCT07202377)
- Testing
- SPECIFIC REVEAL® Rapid AST system, antibiotic susceptibility testing on agar medium
- Volunteers
- 200 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Bacteremia Sepsis
Resistell Phenotech AST to Determine the Antibiotic Susceptibility of Gram-negative Bacteria Causing Bacteremia
The aim of this study is to assess the sensitivity, specificity, and accuracy of the Resistell Phenotech device in testing antibiotic susceptibility of Gram-negative bacteria (i.e., E. coli or K.
- Trial name
- PHENOTECH-1 (NCT05613322)
- Testing
- Resistell Phenotech
- Where
- 3 sites in Austria, Spain and 1 more
- Volunteers
- 246 people
- Sponsor
- Resistell AG
Bacteremia
T2 and SeptiCyte RAPID Duration Project
Infection with bacteria and other germs in the blood can be deadly. How long germs stay in the blood is important for two reasons.
- Trial name
- NCT04821661
- Where
- 3 sites in Australia
- Volunteers
- 102 people
- Sponsor
- The University of Queensland